Bicycle Therapeutics Plc has entered a strategic collaboration with Novartis to pair its peptide technology with Novartis’ experience in radiopharmaceutical development to design new therapies for cancer. The agreement was announced on 28 March and will include a $50 million upfront payment to Bicycle and milestone commitments of up to $1.7 billion. Bicycle’s molecules are synthetic peptides held in place with small molecule scaffolds to form two loops that stabilise the structure. This creates a small binding site for its therapies which are said to achieve very specific targeting.
